NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain. Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and are initiating Phase I clinical trials of NTRX-07 in humans in 2019.
Location: United States, Ohio, Cleveland
Employees: 11-50
Total raised: $21.1M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Dolby Fami... | dolbyventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.08.2024 | Series B | $12.3M | - |
| 22.09.2020 | Series A | $8.8M | - |
Mentions in press and media 6
| Date | Title | Description |
| 06.08.2024 | NeuroTherapia Raises $12.3M in the First Close of its Series B Financing | Investment will allow NeuroTherapia to continue the development of an orally available treatment for Alzheimer's disease. CLEVELAND, Aug. 6, 2024 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company and Cleveland Clinic Innovations... |
| 08.05.2024 | NeuroTherapia Receives Grant from Alzheimer's Association for Development of First-in-Class Drug for Alzheimer's Disease | CLEVELAND, May 8, 2024 /PRNewswire/ -- NeuroTherapia, an early-stage clinical pharmaceutical company, announced today that it has received a grant from the Alzheimer's Association Part the Cloud program for the development of its first-in-c... |
| 25.09.2020 | NeuroTherapia Raises $8.8M in Series A Financing | NeuroTherapia, Inc., a Cleveland, OH-based clinical-stage company focused on developing therapies for neurodegenerative diseases, closed its Series A financing of $8.8M. The round was led by Brain Trust Accelerator Fund II, with participati... |
| 22.09.2020 | NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II | - |
| 22.09.2020 | NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II | |
| 28.12.2016 | Startup Spotlight: Seeking a new path to treat Alzheimer’s by reducing inflammation | The road to find an effective treatment for Alzheimer’s has been long and tortured. Established industry titans have spent many years developing promising drugs, only to see them fail in late-stage trials. NeuroTherapia Inc., a Cleveland Cl... |